CHANGEBLOCK
27.11.2023 11:32:27 CET | Business Wire | Press release
Changeblock, a global sustainability fintech company utilizing advanced data-systems and technologies to accelerate planet repair and protection activities through the generation and exchange trading of high-integrity environmental assets, such as carbon credits, today announced the appointment of Baroness Evans of Bowes Park, former leader of the UK House of Lords, as Senior Advisor, Policy & Ethics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231123431705/en/
Baroness Natalie Evans of Bowes Park, former UK Cabinet Minister as Leader of the House of Lords and Senior Advisor, Policy and Ethics of Changeblock Limited. (Photo: Business Wire)
Trust and integrity are crucial for companies to monetize their planet repair and protect initiatives, and therefore crucial for credits to be adopted at the scale necessary towards achieving net-zero, Consequently, policy and ethics are major focus areas for Changeblock that require integration into the credit value chain. The appointment of Baroness Evans will significantly strengthen the Company’s efforts in this regard, and augments the work already being done with multiple standard and verification agencies.
Baroness Evans commented, “Reducing society’s environmental footprint is one of the most pressing challenges we as humanity are facing today, and tradeable offsets, such as credits, hold great promise towards delivering this. Their effectiveness will be impacted by how the companies in this eco-system engage with policy and policy makers.
“Ethics play an increasingly important role in credit integrity assessments and in investment decision making. Changeblock’s forward, strategic thinking, combined with their unique offering that meets such a critical need, make this an exciting opportunity. I look forward to working with Billy and the team and help Changeblock cement its leadership position as a critical net-zero infrastructure partner.”
Billy Richards, Changeblock CEO, stated, “We believe Baroness Evans is exceptionally well positioned to provide Changeblock with actionable insights, and help us strengthen our position as a critical infrastructure partner for credit generators, off-setters, investors and policy makers. I believe this appointment reflects the importance, integrity and quality of our offering, as well as the depth and strength of our network, and I am excited to be working on these important initiatives with Natalie as we expand our operations and help smooth the path to net-zero.”
Baroness Evans
Baroness Evans of Bowes Park is a Conservative member of the House of Lords. She was appointed a life peer in October 2014, and acted as Leader of the House of Lords and a member of the UK Government’s Cabinet from 2016 to 2022 - the longest serving Leader for 70 years. Between 2015 and 2016 she was a junior Government minister in the Department of Education, Department for Work and Pensions, and the Ministry of Justice. Before entering the Lords, Natalie held a variety of senior positions including CEO of the New Schools Network, Deputy Director of Policy Exchange, and Head of Policy at the British Chambers of Commerce.
Changeblock at COP28
Billy Richards and Baroness Natalie Evans from Changeblock will attend COP28 in Dubai. Changeblock is hosting a roundtable with leaders like David Greenall (KPMG), Jim Andrew (Pepsico), and Michael Terrell (Google), discussing AI analytics in carbon offsetting. The roundtable, titled “The Critical Role of Integrity in Carbon Credits and Offsets for Effective Planet Repair,” will explore sustainable carbon mitigation strategies.
About Changeblock
Changeblock creates global markets that make the creation and trade of environmental assets for individuals, businesses, and governments easy, affordable, transparent, secure, and environmentally responsible. The company is led by professionals with deep expertise in technology and environmental credits with a proven track record in building and delivering solutions that work in the real world, including members of the team that created the first carbon credit, and come from top global organisations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231123431705/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom